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Abstract
Objective: To assess the prognostic and diagnostic value of whole blood impedance aggregometry in patients with sepsis
and SIRS and to compare with whole blood parameters (platelet count, haemoglobin, haematocrit and white cell count).
Methods: We performed an observational, prospective study in the acute setting. Platelet function was determined using
whole blood impedance aggregometry (multiplate) on admission to the Emergency Department or Intensive Care Unit and
at 6 and 24 hours post admission. Platelet count, haemoglobin, haematocrit and white cell count were also determined.
Results: 106 adult patients that met SIRS and sepsis criteria were included. Platelet aggregation was significantly reduced in
patients with severe sepsis/septic shock when compared to SIRS/uncomplicated sepsis (ADP: 90.7637.6 vs 61.4640.6; p,
0.001, Arachadonic Acid 99.9648.3 vs 66.3650.2; p = 0.001, Collagen 102.6633.0 vs 79.1638.8; p = 0.001; SD 6 mean)).
Furthermore platelet aggregation was significantly reduced in the 28 day mortality group when compared with the survival
group (Arachadonic Acid 58.8647.7 vs 91.1650.9; p,0.05, Collagen 36.6636.6 vs 98.0635.1; p = 0.001; SD 6 mean)).
However haemoglobin, haematocrit and platelet count were more effective at distinguishing between subgroups and were
equally effective indicators of prognosis. Significant positive correlations were observed between whole blood impedance
aggregometry and platelet count (ADP 0.588 p,0.0001, Arachadonic Acid 0.611 p,0.0001, Collagen 0.599 p,0.0001
(Pearson correlation)).
Conclusions: Reduced platelet aggregometry responses were not only significantly associated with morbidity and mortality
in sepsis and SIRS patients, but also correlated with the different pathological groups. Whole blood aggregometry
significantly correlated with platelet count, however, when we adjust for the different groups we investigated, the effect of
platelet count appears to be non-significant.
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Introduction
Sepsis is a life threatening condition and common complication
of critical illness [1]. It is characterised by a systemic inflammatory
response to an ongoing infectious process and can lead to
hypotension, multi organ dysfunction (MOD) and death [2].
Systemic inflammation can also have non-infectious causes such as
burns, pancreatitis and ketoacidosis, and is termed systemic
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inflammatory response syndrome (SIRS). Prevalence of SIRS due
to sterile or infectious causes is very high, affecting up to one third
of all hospital patients [3] and it remains a challenge to
differentiate sepsis from sterile SIRS which is vital in guiding
effective treatment.
It has been shown previously that coagulation is activated across
the septic range [4,5] This activation can express itself as either a
mildly increased risk of thrombosis to systemic formation of
intravascular thrombi, known as disseminated intravascular
coagulation (DIC). Altered coagulation contributes to the patho-
genesis and outcome of sepsis. In severe sepsis microthrombi
formation in the vasculature alters perfusion of blood into the
organs, contributing to multiple organ dysfunction syndrome
(MODS) [6]. Sepsis is also the leading cause of thrombocytopenia
[7] which is related to poor outcome [8]. Studies have highlighted
that the function of platelets goes beyond haemostatic regulation
[9,10] and there is increasing evidence that platelets are key
mediators of inflammation and the immunological response to
infection [11]. Platelet aggregation is enhanced in the presence of
lipopolysaccharide (LPS) in vitro [12], which has been identified to
be dependent on toll-like receptor 4 pathway [13]. This suggests
increased platelet aggregation measurements might be observed in
patients with sepsis.
The role of platelet aggregation is very important in inflamma-
tion. In severe sepsis, platelet aggregation has been often shown to
be decreased [14][15][16]; however, this has yet to be investigated
in the whole sepsis spectrum. Whole blood impedance aggrego-
metry (multiplate) is a point of care test that can be used to
measure platelet aggregation in response to different agonists and
has been shown to be a predictor of diagnosis and prognosis in
patients with severe sepsis [15]. However, it has also been
suggested that whole blood impedance aggregometry is dependent
on whole blood parameters (platelet count, haematocrit, haemo-
globin and white cell count) [17][18]. Of particular relevance to
whole blood impedance aggregometry are platelet counts of less
than 1506109/L [19].
The primary aim of this study was to assess the diagnostic and
prognostic accuracy of whole blood aggregometry in patients who
present across the septic range and to compare these results against
the whole blood parameters (platelet count, white cell count,
haematocrit and haemoglobin). The secondary aim of the study
was to investigate the dependence of whole blood aggregometry on
the whole blood parameters.
Materials and Methods
Ethical Approval
Full ethical approval was given by the South West Wales
Research Ethics Committee. Informed 2-stage written consent was
given by patients with capacity to do so. Assent was obtained from
personal or legal representation in cases where capacity to give
informed consent was lacking.
Patients
A total of 106 patients were recruited from October 2011 to
November 2013 in a large teaching hospital in Wales. All patients
were considered eligible as per the SIRS criteria defined in 2003
[20]. 42 healthy volunteers from a similar demographic population
group and matched for gender and age were recruited as a control
group. Patients with any disease that affects the coagulation profile
including liver cirrhosis and renal disease were excluded. Patients
that had received anticoagulant therapy were also excluded.
Patient outcome was evaluated at 28 days.
Sepsis-related Organ Failure Assessment (SOFA) score [21] was
determined over the first 24 hours to assess organ function.
Patients were assigned to groups as follows: 1) Sterile SIRS 2)
Uncomplicated sepsis 3) Severe sepsis 4) Septic shock as per the
criteria defined in 2003 [20]. Assignment into groups was blinded
and performed by an experienced intensive care specialist
independent of the study. All platelet aggregation data was also
validated independently.
Table 1. Demographics of Subject Groups.
Healthy SIRS Sepsis Severe Sepsis Septic Shock
Number 42 21 42 17 26
Male (%) 21 (50.0) 12 (57.1) 19 (45.2) 8 (47.1) 16 (61.5)
Age (Years) 60.1616.5 62.8620.4 56.6619.6 63.9621.4 68.6613.0
Primary Site of Infection
Respiratory Tract (%) - - 27 (64.3) 10 (58.8) 10 (38.5)
Urinary Tract (%) - - 7 (16.7) 4 (23.5) 6 (23.1)
GI Tract (%) - - 3 (7.1) 0 (0) 6 (23.1)
Other (%) - - 5 (11.9) 3 (17.6) 4 (15.4)
Comorbidities
Diabetes Mellitus (%) 0 (0) 12 (57.1) 4 (9.5) 4 (23.5) 9 (34.6)
COPD (%) 0 (0) 3 (14.3) 19 (45.2) 2 (11.8) 4 (15.4)
Congestive Heart Failure (%) 0 (0) 2 (9.5) 1 (2.4) 0 (0) 2 (7.7)
Active Cancer (%) 0 (0) 0 (0) 1 (2.4) 0 (0) 3 (11.5)
28 Day Mortality (%) - 2 (9.5) 1 (2.4) 0 (0) 3 (11.5)
SOFA Score - 3 (2, 7) 3 (1.25, 3) 5 (4, 6) 9 (6, 12)
Hospital LOS (days) - 6 (4.5, 14.5) 5 (2, 8.5) 9 (5.5, 19) 14 (2.5, 43)
COPD = Chronic Obstructive Pulmonary Disease; SOFA = Sepsis-relates Organ Failure Assessment; LOS = Length of Stay.
doi:10.1371/journal.pone.0108589.t001
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Blood Sampling
Blood was drawn at time of admission to the emergency
department or intensive care unit, at 6 hours and 24 hours post
admission to assess disease progression and the effect of treatment.
For multiplate analysis, blood was drawn into 3mL hirudin blood
tubes (Verum Diagnostica, Munich, Germany) as per manufac-
turers’ recommendations. Testing was performed 20 minutes after
the blood was drawn. A total volume of 300 mL of hirudinised
blood was added to 300 mL normal saline in the multiplate test
cell, which was then incubated at 37uC for 3 minutes. Blood
samples were then activated using three different reagents 1)
adenosine diphosphate (ADP test, Verum Diagnostica GmbH), 2)
arachadonic acid test of cyclooxygenase activity (ASPI test, Verum
Diagnostica GmbH) and 3) collagen (COL test, Verum Diag-
nostica GmbH) agonists. Aggregometry measurements were
assessed via the area under the curve measurement (arbitrary
units).
A 4 ml aliquot of blood was taken for full blood count (FBC)
analysis to determine all the whole blood parameters. Samples
were collected into plastic, full-draw dipotassium EDTA Vacuettes
(Greiner Bio-One, Stonehouse, UK Ref: 454286). FBC was
analysed using a Sysmex XE 2100 (Sysmex UK, Milton Keynes,
UK) automated haematology analyser within 2 hrs of collection.
Statistical Analysis
All statistical analysis was carried out on GraphPad Prism
version 6 (GraphPad software, La Jolla, CA, USA). Values are
given as mean and standard deviation or alternatively median and
quartiles. For continuous variables T-test was used to detect
significant differences between normally distributed groups and
Figure 1. Comparison of platelet aggregometry measurements in different pathological groups and healthy control. Platelet
aggregation measurements induced by ADP, ASPI and Collagen agonists are shown in the different pathological groups and healthy control.
Aggregometry measurements are expressed as area under the curve (AUC, arbitrary units). Significant differences between the groups are indicated
by p-values, as assessed by Bonferroni post-hoc analysis.
doi:10.1371/journal.pone.0108589.g001
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Kruskal-Wallis was used to detect differences in non-normally
distributed data. Data normality was assessed using the Kolmo-
gorov-Smirnov and Shapiro-Wilk tests using an a of 0.05.
Bonferroni post hoc correction was used to assess multiple
comparisons across groups. Receiver operating characteristics
were determined to assess discrimination between groups.
Sensitivities and specificities were determined from the optimal
cut-off values, which were calculated as the point at which the
Youden Index was maximised [22].
Pearson’s correlation coefficient was used to investigate
relationships between whole blood aggregometry and whole blood
parameters. Analysis of Covariance (ANCOVA) was used to adjust
for changes in platelet aggregation in the different groups
investigated, with the platelet count as a covariate using the
General Linear Model method.
To adjust for the effect of low platelet count on whole blood
impedance aggregometry, data was reanalysed for patients with
platelet counts greater than 1006109/L only.
Statistical significance was defined as a p-value of less than 0.05
(two-tailed).
Results
Platelet aggregometry and full blood count were assessed in a
total of 106 patients that met SIRS criteria. This included 21
SIRS, 42 uncomplicated sepsis, 17 severe sepsis and 26 septic
shock patients. A healthy group of 42 volunteers was also
recruited. Clinical characteristics are presented in Table 1.
Figure 2. Comparison of whole blood parameters in different pathological groups and healthy control. Platelet count, white cell count,
haemoglobin and haematocrit measurements are shown in different pathological groups and healthy control. Significant differences between the
groups are indicated by p-values, as assessed by Bonferroni post-hoc analysis.
doi:10.1371/journal.pone.0108589.g002
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Platelet Aggregometry for Diagnosing Sepsis Severity
The results, shown in Figure 1, demonstrate reduced platelet
aggregometry values in patients with severe sepsis and septic shock
when compared to SIRS and uncomplicated sepsis when ADP and
ASPI were used as the agonist, but this was not the case when
Collagen was used as the agonist. Platelet aggregometry values in
the patient groups were comparable to those of the healthy group.
Results for haemoglobin, haematocrit, platelet count and white
cell count are presented in Figure 2. Significant progressive
reductions in haemoglobin, haematocrit and platelet count were
observed across the sepsis spectrum, with increasing severity.
White cell count was elevated in all patient groups when compared
to the healthy group.
Platelet Aggregometry for the Diagnosis of Severe Sepsis
To assess platelet aggregometry as a diagnostic marker of severe
sepsis, patients were assigned to two groups: SIRS/uncomplicated
sepsis and severe sepsis/septic shock. The results, displayed in
Table 2, show significantly reduced platelet aggregation, haemo-
globin, haematocrit and platelet count in patients with severe
sepsis/septic shock when compared to SIRS/uncomplicated sepsis
patients.
To further assess discrimination between SIRS/uncomplicated
sepsis and severe sepsis/septic shock groups, receiver operating
characteristics were analysed (Figure 3). The corresponding area
under the curve and significance are shown in Table 3. All
parameters except for white cell count showed significant
discrimination between groups as defined by p-values of less than
0.05. This indicates that whole blood impedance aggregometry is
able to distinguish between those with SIRS/uncomplicated sepsis
and severe sepsis/septic shock, particularly when ADP is used as
the agonist. The most significant discriminatory power, apart from
SOFA score, was observed with ADP aggregometry, haematocrit
and platelet count.
Optimal cut-off points were determined as described in the
methods section. Sensitivity, specificity and the optimal cut-off for
each parameter are displayed in Table 4.
Platelet Aggregometry for Determining Prognosis in
Sepsis Patients
All patients were followed up for 28-day mortality. Character-
istics of 28 day survival and mortality groups are shown in
Table 5. Platelet aggregometry was significantly reduced in the 28-
day mortality group using ASPI and COL agonists; however, with
ADP activation this did not appear to be the case. Haemoglobin,
platelet count and white cell count were all significantly reduced in
Table 2. Comparison of SIRS/Uncomplicated sepsis and severe sepsis/septic shock.
Healthy
(n =42)
SIRS/Uncomplicated
Sepsis (n =62)
Severe
Sepsis/Septic
Shock (n =43)
Significance value
(Healthy vs
SIRS/Uncomplicated)
Significance Value
(SIRS/Uncomplicated vs
Severe/Septic Shock
ADP (AUC) 80.4621.1 90.7637.6 61.4640.6 NS ,0.001
ASPI (AUC) 93.2624.3 99.9648.3 66.3650.2 NS 0.001
COL (AUC) 85.5619.0 102.6633.0 79.1638.8 0.01 0.001
Platelet
Count (109/L)
255.6651.9 295.06110.9 192.56103.2 0.03 ,0.001
White Cell
Count (109/L)
6.261.5 17.966.7 15.269.9 ,0.001 NS
Haemoglobin
(g/dL)
14.361.3 13.062.0 11.062.5 ,0.001 ,0.001
Haematocrit (%) 0.4260.04 0.3960.06 0.3360.07 0.01 ,0.001
doi:10.1371/journal.pone.0108589.t002
Figure 3. Receiver operating characteristics for discrimination
between SIRS/Uncomplicated Sepsis and Severe Sepsis/Septic
Shock groups. Receiver operating characteristics are shown for
platelet aggregometry measurements, whole blood parameters and
sepsis-related organ failure assessment (SOFA) score as a discriminator
between patients with and without organ dysfunction.
doi:10.1371/journal.pone.0108589.g003
Figure 4. Receiver operating characteristics for discrimination
between survivors and non-survivors at 28 days. Receiver
operating characteristics are shown for platelet aggregometry mea-
surements and whole blood parameters for the discrimination between
28-day mortality and survival.
doi:10.1371/journal.pone.0108589.g004
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the 28-day mortality group. Receiver operating characteristic
curves showing discrimination between survivors and non-
survivors are shown in Figure 4. The AUC, significance and
confidence intervals are shown in Table 6. All measured
parameters showed significant discrimination between survivors
and non-survivors (Asymptomatic Sig ,0.05). This indicates
reduced whole blood parameters and impaired platelet function
are strongly related to poor outcome in sepsis patients.
Effect of Treatment on Platelet Aggregation
To assess the effect of treatment and disease progression on
platelet aggregation, measurements were repeated at 6 and
24 hours post admission. The results, shown in Figure 5,
demonstrate a significant reduction in ADP induced aggregation
over 24 hours in the SIRS and uncomplicated sepsis groups.
Haemoglobin and haematocrit were also significantly reduced
over 24 hours in uncomplicated sepsis. No other significant
changes were observed in any of the groups over 24 hours.
Reduced platelet aggregation and whole blood parameters were
observed in the more severe groups over the 24 hours; however,
this was not significant.
Dependence of Platelet Aggregometry on Whole Blood
Parameters
Correlation analysis was used to assess the dependence of
platelet aggregometry on platelet count, haemoglobin and
leukocyte count. Platelet aggregation correlated significantly with
all blood count parameters (Table 7). Using correlation analysis,
R2 values were 0.363, 0.420 and 0.379 (p,0.001) for ADP, ASPI
and Collagen agonists respectively.
Analysis of the effect of platelet count on platelet aggregation
using all three aggregating agents and using Analysis of
Covariance (General Linear Model) would suggest that the platelet
count significantly affects platelet aggregation, however, the
change in platelet aggregation for ADP, collagen and aspirin is
significantly different in the sepsis and non-sepsis groups even
when we adjust for the platelet count (P,0.005, ANCOVA).
Hence, this analysis would support the view that sepsis has an
effect on both the platelet count together with platelet function.
Adjusting for Low Platelet Count
To correct for the potential effects low platelet count had on
Multiplate readings, data was reanalysed for patients with a
platelet count greater than 1006109/L (n = 97). Platelet aggrego-
metry using all three agonists (ADP, ASPI and collagen) remained
significant at distinguishing between SIRS/uncomplicated sepsis
and severe sepsis/septic shock (ADP 68.8639.9 vs 90.7637.6, p,
Table 3. Receiver Operating Characteristics for the Diagnosis of Severe Sepsis.
Test Result Variable(s) Area Std. Error
Asymptomatic
Sig.
Asymptomatic 95%
Confidence Interval
(Lower Bound)
Asymptomatic 95%
Confidence Interval
(Upper Bound)
ADP (AUC) 0.740 0.051 ,0.001 0.640 0.840
ASPI (AUC) 0.697 0.054 0.001 0.592 0.802
COL (AUC) 0.689 0.055 0.001 0.582 0.796
Platelet Count (109/L) 0.759 0.049 ,0.001 0.664 0.855
White Cell Count (109/L) 0.608 0.060 0.061 0.491 0.726
Haemoglobin (g/L) 0.722 0.052 ,0.001 0.620 0.823
Haematocrit (%) 0.746 0.051 ,0.001 0.646 0.846
SOFA 0.870 0.036 ,0.001 0.799 0.942
SOFA = Sepsis-related Organ Failure Assessment score.
doi:10.1371/journal.pone.0108589.t003
Table 4. Sensitivity and Specificity for the Diagnosis of Severe Sepsis.
Cutoff Sensitivity (%) Specificity (%)
ADP ,75.5 75.6 71.9
ASPI ,85.5 73.2 64.9
COL ,62.5 48.8 93
Platelet Count ,211.5 61 80.7
White Cell Count ,12.35 48.8 82.5
Haemoglobin ,11.35 58.5 86
Haematocrit ,0.322 53.7 91.2
SOFA.3.5 92.7 71.9
Sensitivity: Percentage of severe sepsis patients with a positive test.
Specificity: Percentage of SIRS/uncomplicated sepsis patients with a negative test.
SOFA = Sepsis-related Organ Failure Assessment score.
doi:10.1371/journal.pone.0108589.t004
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0.05; ASPI 76.4650.7 vs 99.9648.3, p,0.05; COL 85.7637.8 vs
102.6633.0, p,0.05). All measured parameters except for ADP
aggregometry remained significantly lower in the 28-day mortality
group (p,0.05).
Discussion
This, to our knowledge, is the first study to assess whole blood
aggregometry across the entire pathological spectrum of SIRS and
sepsis. The data demonstrates that a reduction in aggregometry
measurements, haemoglobin and platelet count are associated with
increasing severity of sepsis. Several authors have reported and
reviewed that platelet function as well as platelet count is
significantly modulated during sepsis-in particular severe sepsis
[4,15,23]. Our data supports these findings in that our analysis
demonstrated both a significant reduction and a significant
modulation of platelet aggregation mediated through all three
agonists used herein. Platelets display a number of properties
besides repairing damaged vascular endothelium and preventing
bleeding. It is known that platelets act to induce pro-inflammatory
events [24] and can engage infectious pathogens [25]. The
sophisticated interplay of platelets with bacteria may culminate in
sepsis that is characterized by significant progressive reductions in
platelet count and platelet function with increasing severity of the
sepsis. This study supports the view that significant changes in
platelet count occur during sepsis. Although there was a reduction
in platelet count with progression of sepsis, our findings showed
that there was also a marked decrease in platelet activity.
As a marker of prognosis, haemoglobin was found to be a highly
significant predictor of 28-day mortality, which has been described
previously [26]. Low platelet count, white cell count and platelet
aggregometry by ASPI and collagen activation were also
significantly associated with mortality, but this was not the case
when ADP was used as the agonist. The significant association
between ADP aggregometry and severity but not mortality is
interesting and could provide insight into the progression of some
of the pathogenic mechanisms of sepsis. Previous studies have
suggested that anti-platelet therapy could be beneficial in critically
ill patients by reducing microvascular thrombi formation and
hence improving perfusion [27,28]. It is possible that platelet
responses to ADP could be blunted if platelets have been exposed
to ADP in vivo, as previously it has been shown that platelets
exposed to ADP become desensitised, and unresponsive to
restimulation [29]. This is a cause for concern in patients in
which there is a degree of haemolysis as ADP released from the
red cells could cause platelet refractoriness to further agonist
exposure. This could be an additional mechanism for the reduced
ADP responses observed in the severe sepsis and septic shock
groups.
Reduced platelet aggregometry measurements were observed in
patients with severe sepsis and septic shock when compared to
SIRS and uncomplicated sepsis. Previously it has been hypothe-
sised that reduced platelet aggregation might be observed in severe
sepsis and septic shock as consumption of platelets with increased
activation occurs due to the hypercoagulable state and endothelial
dysfunction [30]. This suggests that platelet aggregometry could be
a biomarker of endothelial function and the level of ongoing DIC.
The findings in this study support previous studies that have
observed reduced platelet aggregometry in patients with severe
Table 5. Characteristics of Survivors and Non-Survivors in Relation to Platelet Aggregation and Whole Blood Parameters.
28 Day Survival (n =89) 28 Day Mortality (n=16) Significance value
ADP (AUC) 81.6639.2 62.9649.8 0.097
ASPI (AUC) 91.1650.9 58.8647.7 0.02
COL (AUC) 98.0635.1 64.8636.6 0.001
Platelet Count (109/L) 268.36117.7 174.4691.9 0.003
White Cell Count (109/L) 17.867.6 11.369.2 0.003
Haemoglobin (g/dL) 12.662.2 9.762.1 ,0.001
Haematocrit (%) 0.3860.06 0.3060.06 ,0.001
Comparisons were made using two-sample t-test.
doi:10.1371/journal.pone.0108589.t005
Table 6. Receiver Operating Characteristics for Survivors and Non-Survivors for Platelet Aggregation and Whole Blood Parameters.
Test Result Variable(s) Area Std. Error
Asymptomatic
Sig.
Asymptomatic 95%
Confidence Interval
(Lower Bound)
Asymptomatic 95%
Confidence
nterval
(Upper Bound)
ADP (AUC) .675 .079 0.027 .521 .829
ASPI (AUC) .686 .072 0.018 .546 .827
COL (AUC) .777 .075 ,0.001 .631 .924
Platelet Count (109/L) .750 .068 0.001 .616 .884
White Cell Count (109/L) .731 .083 0.003 .568 .895
Haemoglobin (g/L) .822 .055 ,0.001 .714 .930
Haematocrit (%) .811 .053 ,0.001 .707 .914
doi:10.1371/journal.pone.0108589.t006
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sepsis [15,16]. Furthermore, this study demonstrates that platelet
aggregometry measurements using collagen as the agonist were
significantly increased in patients with uncomplicated sepsis/sirs
compared to healthy volunteers. However, this was not the case
Figure 5. Effect of treatment and disease progression on platelet aggregation and whole blood parameters. Platelet aggregation and
whole blood parameters were measured at baseline, 6 hours and 24 hours are shown. *Significant result (P,0.05), two-sample t-test.
doi:10.1371/journal.pone.0108589.g005
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when using ADP or ASPI agonists. The data presented in this
study suggests that platelet count and haemoglobin are equally as
effective as whole blood impedance aggregometry as diagnostic
and prognostic tools in patients that meet SIRS and sepsis criteria.
The strong relationship between haemoglobin and sepsis severity
and outcome is an interesting one. It is clear from the literature
that red blood cell derangement is common occurrence in severe
sepsis and this contributes to impairment of the microcirculation
leading to eryptosis and reduced circulating haemoglobin [31,32].
Consequently haemoglobin measurements could be providing
information on micro perfusion and hence organ dysfunction.
Recent studies has also highlighted the impact low haemoglobin
level have on blood CO2 binding capacity [33]. This suggests
anaemia could contribute to acidosis, and enhance coagulopathy
in sepsis.
We observed that different agonists yielded different operating
characteristics when assessing diagnosis and prognosis. This can be
explained as each of these agonists causes activation of platelets via
a different route e.g. ADP through the P2Y receptors, ASPI
through COX-1 cyclooxygenase pathway and Collagen through
glycoprotein VI and therefore display different strengths in their
ability to activate platelets, some being more effective activators
than others. In SIRS/sepsis patients, it could be the case that this
variability is heightened.
When assessing the effect of platelet count on platelet
aggregation, significant correlations were observed. Furthermore,
when excluding subjects with a low platelet count from the
analysis, platelet aggregation remained significantly reduced with
relation to severity and poor outcome. Although platelet aggre-
gation values are affected by platelet count, variability exists in
both platelet count and platelet function in the healthy range and
it is also possible to achieve normal aggregometry readings at low
platelet counts [18]. Therefore, taking into account the limitations
of the assay, there remains a trend to significantly reduced platelet
function with increasing severity of disease in this study
population.
Limitations
This large pilot observational study has a number of limitations.
The inherent problem of this and other reported studies is the
heterogeneity of the disease, treatment and comorbidities. It is also
difficult to take into account differences in medication and
treatment between groups, and to assess this fully, a much larger
number of patients would be required. In order to overcome some
of these limitations we implemented tight inclusion/exclusion
criteria and excluded patients that were receiving anticoagulant
therapy at baseline. Sample size could be viewed as a limitation in
this study; however, the sample size was powerful enough for us to
detect several significant differences between groups. Further
larger prospective studies are required to build on the findings of
this study.
Conclusions
This study supports the view that significant changes in platelet
function occur across the sepsis spectrum, possibly due to different
pathophysiological mechanisms. There remains a trend towards
worsening platelet function with increasing severity in patients
with SIRS and sepsis that is independent of platelet count.
Furthermore, our study demonstrates that haemoglobin and
platelet count have greater diagnostic and prognostic value than
whole blood impedance aggregometry measurements in patients
with SIRS and sepsis. This research further highlights the
importance of red blood cells and platelet count in patients with
SIRS and sepsis and the potential benefits therapeutic intervention
addressing red blood cell rheology and function could have.
Further larger studies are now required to explore and determine
how the mechanistic role of platelet activity and change across the
sepsis spectrum is related to the disease process and outcome.
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